Armata Pharmaceuticals announced progress in preparing for the Phase 3 superiority study of AP-SA02, a bacteriophage therapy for antibiotic-resistant Staphylococcus aureus infections. The company received FDA Breakthrough Therapy designation and additional funding from the U.S. Department of War to support clinical development. In Q3 2026, Armata reported a net income of $54.9 million, largely due to a $69.6 million gain from changes in the fair value of a convertible loan, despite operational losses. The Phase 3 trial is expected to start in the second half of 2026, pending FDA approval of the study protocol.
Armata Pharmaceuticals financial results provide context for readers. For those following health-sector stocks, 23 out of 150 US stocks rose and 124 fell on Pluang. Notable movers as of Nov 13, 2026 04:11 WIB include RXRX at USD 3.34 (-6.96%), HRTX at USD 0.33 (-6.90%), and TWST at USD 114.14 (-6.89%).
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
